Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Geriatrics Reports
Erschienen in:

Open Access 28.07.2017 | Nutrition, Obesity, and Diabetes (H Florez, Section Editor)

Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes

verfasst von: Michael Quartuccio, Brian Buta, Rita Rastogi Kalyani

Erschienen in: Current Geriatrics Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to summarize the current data for comparative effectiveness of glycemic control in older adults.

Recent Findings

In the last several years, professional societies have released guidelines for glycemic control in older adults, generally recommending individualized HbA1c goals. However, recent observational studies demonstrate that many older adults remain aggressively managed and are at increased risk of hypoglycemia. Large randomized trials of older adults with diabetes have failed to show convincing cardiovascular benefit from intensive glycemic control and suggest some microvascular benefit. Additionally, a few studies suggest that suboptimal glycemic control can increase the risk for geriatric syndromes. Emerging research suggests similar safety and efficacy of glucose-lowering therapies in older versus younger adults.

Summary

Overall, there is a paucity of data supporting the benefit of intensive glycemic control in older adults. More research is needed in this vulnerable population.
Literatur
1.
American Diabetes Association. 11. Older adults. Diabetes Care. 2017;40(Suppl 1):S99–S104.CrossRef
2.
American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus, Moreno G, Mangione CM, Kimbro L, Vaisberg E. Guidelines abstracted from the American Geriatrics Society Guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11):2020–6.CrossRef
3.
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(Suppl 1):1–87.PubMedPubMedCentralCrossRef
4.
5.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.PubMedCrossRef
6.
Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquin B, Sanchez-Castellano C, Sanchez-Garcia E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(5):734–8.PubMedCrossRef
7.
Muller N, Khunti K, Kuss O, et al. Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetol. 2016;54(2):209–14.PubMedCrossRef
8.
Twito O, Ahron E, Jaffe A, et al. New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization. Diabetes Care. 2013;36(11):3425–9.PubMedPubMedCentralCrossRef
9.
Palta P, Huang ES, Kalyani RR, Golden SH, Yeh HC. Hemoglobin A1c and mortality in older adults with and without diabetes: results from the national health and nutrition examination surveys (1988–2011). Diabetes Care. 2017;40(4):453–60.PubMedPubMedCentralCrossRef
10.
Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34(6):1329–36.PubMedPubMedCentralCrossRef
11.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352(9131):837–53.
12.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMed
13.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.PubMedCrossRef
14.
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef
15.
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–206.PubMedCrossRef
16.
Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–406.PubMedCrossRef
17.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRef
18.
Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Diabetes Care. 2014;37(3):634–43.PubMedPubMedCentralCrossRef
19.
20.
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.PubMedCrossRef
21.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.PubMedCrossRef
22.
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.PubMedCrossRef
23.
•• Bethel MA, Engel SS, Green JB, et al. Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care. 2017;40(4):494–501. This recent study stratified rates of cardiovascular outcomes associated with sitagliptin by age, specifically focusing on adults ≥65 versus those younger. Though a neutral effect was observed, it highlights the importance of exploring cardiovascular outcomes of medications in older adults, who are often excluded from randomized medication trials. PubMedCrossRef
24.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.CrossRefPubMed
25.
26.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.CrossRefPubMed
27.
28.
29.
30.
•• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. This randomized trial showed reduction in composite cardiovascular endpoints in the overall group and in a subgroup of older adults. It highlights how further trials should study differential effects in older adults. CrossRefPubMed
31.
32.
33.
34.
ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.CrossRef
35.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938–53.CrossRefPubMed
36.
Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitao C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016;13(4):e1001992.PubMedPubMedCentralCrossRef
37.
Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634–43.PubMedCrossRef
38.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.PubMedCrossRef
39.
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411–8.PubMedCrossRef
40.
Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166(2):240–249.e1.PubMedCrossRef
41.
Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–11.PubMedPubMedCentralCrossRef
42.
Holman RR, Bethel MA, Chan JC, et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J. 2014;168(1):23–9.e2.PubMedCrossRef
43.
Herrmann K, Zhou M, Wang A, de Bruin T. Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials. Clin Diabetes Endocrinol. 2016;2(12):1–8.
44.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–43.PubMedCrossRef
45.
Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13.PubMedPubMedCentralCrossRef
46.
Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740–51.PubMedCrossRef
47.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.PubMedPubMedCentralCrossRef
48.
Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.PubMedPubMedCentralCrossRef
49.
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30.PubMedPubMedCentralCrossRef
50.
ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–44.CrossRef
51.
Carlson C, Merel SE, Yukawa M. Geriatric syndromes and geriatric assessment for the generalist. Med Clin North Am. 2015;99(2):263–79.PubMedCrossRef
52.
Kuchel GA. Aging and homeostatic regulation. In: Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S, editors. Hazzard’s geriatric medicine and gerontology. 6th ed. New York: McGraw-Hill; 2009.
53.
Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–91.PubMedPubMedCentralCrossRef
54.
Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm—issues and controversies. J Gerontol A Biol Sci Med Sci. 2007;62(7):731–7.PubMedCrossRef
55.
56.
Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161(16):1989–96.PubMedCrossRef
57.
Wang T, Lu J, Wang W, et al. Sleep duration and snoring associate with hypertension and glycaemic control in patients with diabetes. Diabet Med. 2015;32(8):1001–7.PubMedCrossRef
58.
Lee SJ, Karter AJ, Thai JN, Van Den Eeden SK, Huang ES. Glycemic control and urinary incontinence in women with diabetes mellitus. J Women's Health (Larchmt). 2013;22(12):1049–55.CrossRef
59.
Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–82.PubMedPubMedCentralCrossRef
60.
Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989–95.PubMedPubMedCentralCrossRef
61.
Noale M, Veronese N, Cavallo Perin P, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016;53(2):323–30.PubMedCrossRef
62.
Gao Y, Xiao Y, Miao R, et al. The prevalence of mild cognitive impairment with type 2 diabetes mellitus among elderly people in china: a cross-sectional study. Arch Gerontol Geriatr. 2016;62:138–42.PubMedCrossRef
63.
West RK, Ravona-Springer R, Schmeidler J, et al. The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control. Am J Geriatr Psychiatry. 2014;22(10):1055–9.PubMedPubMedCentralCrossRef
64.
Ravona-Springer R, Heymann A, Schmeidler J, et al. Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes. PLoS One. 2014;9(6):e97384.PubMedPubMedCentralCrossRef
65.
Hirabayashi N, Hata J, Ohara T, et al. Association between diabetes and hippocampal atrophy in elderly Japanese: the Hisayama study. Diabetes Care. 2016;39(9):1543–9.PubMedCrossRef
66.
67.
Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969–77.PubMedPubMedCentralCrossRef
68.
Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300–6.PubMedPubMedCentralCrossRef
69.
Chin SO, Rhee SY, Chon S, et al. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract. 2016;122:54–61.PubMedCrossRef
70.
Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38(4):588–95.PubMedPubMedCentralCrossRef
71.
Prinz N, Stingl J, Dapp A, et al. High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: a multicenter cohort study on 215,932 patients from the German/Austrian Diabetes Registry. Diabetes Res Clin Pract. 2016;112:73–81.PubMedCrossRef
72.
Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35(4):787–93.PubMedPubMedCentralCrossRef
73.
Kalyani RR, Egan JM. Diabetes and altered glucose metabolism with aging. Endocrinol Metab Clin N Am. 2013;42(2):333–47.CrossRef
74.
Fuller-Thomson E, Yu B, Nuru-Jeter A, Guralnik JM, Minkler M. Basic ADL disability and functional limitation rates among older AMERICANS from 2000–2005: the end of the decline? J Gerontol A Biol Sci Med Sci. 2009;64(12):1333–6.PubMedCrossRef
75.
Lin SF, Beck AN, Finch BK, Hummer RA, Masters RK. Trends in US older adult disability: exploring age, period, and cohort effects. Am J Public Health. 2012;102(11):2157–63.PubMedPubMedCentralCrossRef
76.
Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55(4):M221–31.CrossRefPubMed
77.
Vestergaard S, Patel KV, Walkup MP, et al. Stopping to rest during a 400-meter walk and incident mobility disability in older persons with functional limitations. J Am Geriatr Soc. 2009;57(2):260–5.PubMedCrossRef
78.
Godino JG, Appel LJ, Gross AL, et al. Diabetes, hyperglycemia, and the burden of functional disability among older adults in a community-based study. J Diabetes. 2017;9(1):76–84.PubMedCrossRef
79.
Kalyani RR, Tian J, Xue QL, et al. Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J Am Geriatr Soc. 2012;60(9):1701–7.PubMedPubMedCentralCrossRef
80.
Kalyani RR, Tra Y, Egan JM, Ferrucci L, Brancati F. Hyperglycemia is associated with relatively lower lean body mass in older adults. J Nutr Health Aging. 2014;18(8):737–43.PubMedPubMedCentralCrossRef
81.
Bandeen-Roche K, Seplaki CL, Huang J, et al. Frailty in older adults: a nationally representative profile in the United States. J Gerontol A Biol Sci Med Sci. 2015;70(11):1427–34.PubMedPubMedCentralCrossRef
82.
Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination survey (NHANES), 1999–2006. Diabetes Care. 2010;33(5):1055–60.PubMedPubMedCentralCrossRef
83.
Yau CK, Eng C, Cenzer IS, Boscardin WJ, Rice-Trumble K, Lee SJ. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc. 2012;60(7):1215–21.PubMedPubMedCentralCrossRef
84.
Abbatecola AM, Bo M, Armellini F, et al. Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: results from the DIMORA study. Metabolism. 2015;64(11):1500–6.PubMedCrossRef
85.
86.
Florez H, Pan Q, Ackermann RT, et al. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012;27(12):1594–601.PubMedPubMedCentralCrossRef
87.
88.
Martin FC. Falls risk factors: assessment and management to prevent falls and fractures. Can J Aging. 2011;30(1):33–44.PubMedCrossRef
89.
Sleet DA, Moffett DB, Stevens J. CDC’s research portfolio in older adult fall prevention: a review of progress, 1985–2005, and future research directions. J Saf Res. 2008;39(3):259–67.CrossRef
90.
Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;9:CD007146. doi(9):CD007146.
91.
Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc. 2007;55(12):2041–4.PubMedCrossRef
92.
Davis KL, Wei W, Meyers JL, Kilpatrick BS, Pandya N. Association between different hemoglobin A1c levels and clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus. J Am Med Dir Assoc. 2014;15(10):757–62.PubMedCrossRef
93.
Chiba Y, Kimbara Y, Kodera R, et al. Risk factors associated with falls in elderly patients with type 2 diabetes. J Diabetes Complicat. 2015;29(7):898–902.CrossRef
94.
Wu TY, Chie WC, Yang RS, et al. Factors associated with falls among community-dwelling older people in Taiwan. Ann Acad Med Singap. 2013;42(7):320–7.PubMed
95.
Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012;35(7):1525–31.PubMedPubMedCentralCrossRef
96.
Ambrose AF, Cruz L, Paul G. Falls and fractures: a systematic approach to screening and prevention. Maturitas. 2015;82(1):85–93.PubMedCrossRef
97.
98.
Panula J, Pihlajamaki H, Mattila VM, et al. Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord. 2011;12:105. -2474-12-105 PubMedPubMedCentralCrossRef
99.
Conway BN, Long DM, Figaro MK, May ME. Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Res Clin Pract. 2016;115:47–53.PubMedPubMedCentralCrossRef
100.
Li CI, Liu CS, Lin WY, et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res. 2015;30(7):1338–46.PubMedCrossRef
101.
Puar TH, Khoo JJ, Cho LW, et al. Association between glycemic control and hip fracture. J Am Geriatr Soc. 2012;60(8):1493–7.PubMedCrossRef
102.
Oei L, Zillikens MC, Dehghan A, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care. 2013;36(6):1619–28.PubMedPubMedCentralCrossRef
103.
Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(7):634–43.PubMedCrossRef
104.
105.
Choi J, Ahn A, Kim S, Won CW. Global prevalence of physical frailty by Fried’s criteria in community-dwelling elderly with national population-based surveys. J Am Med Dir Assoc. 2015;16(7):548–50.PubMedCrossRef
106.
Buta BJ, Walston JD, Godino JG, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53–61.PubMedCrossRef
107.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.CrossRefPubMed
108.
Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: characterization in the women’s health and aging studies. J Gerontol A Biol Sci Med Sci. 2006;61(3):262–6.CrossRefPubMed
109.
110.
Garcia-Esquinas E, Graciani A, Guallar-Castillon P, Lopez-Garcia E, Rodriguez-Manas L, Rodriguez-Artalejo F. Diabetes and risk of frailty and its potential mechanisms: a prospective cohort study of older adults. J Am Med Dir Assoc. 2015;16(9):748–54.PubMedCrossRef
111.
Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–8.PubMedPubMedCentralCrossRef
112.
Fu H, Xie W, Curtis B, Schuster D. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Curr Med Res Opin. 2014;30(9):1787–93.PubMedCrossRef
113.
ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care. 2015;38(1):22–8.CrossRef
114.
•• Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174(7):1116–24. This review of current practice shows how many older adults still glycemic targets lower than recommended by most societies for older patients. PubMedPubMedCentralCrossRef
115.
Huang CC, Weng SF, Tsai KT, et al. Long-term mortality risk after hyperglycemic crisis episodes in geriatric patients with diabetes: a national population-based cohort study. Diabetes Care. 2015;38(5):746–51.PubMedCrossRef
116.
Hsu A, Gan S, Cenzer-Stijacic I, Lee SJ. Glycemic control and functional decline in nursing home residents with diabetes. JAMA Intern Med. 2017;177(1):130–2.PubMedPubMedCentralCrossRef
117.
Metadaten
Titel
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
verfasst von
Michael Quartuccio
Brian Buta
Rita Rastogi Kalyani
Publikationsdatum
28.07.2017
Verlag
Springer US
Erschienen in
Current Geriatrics Reports / Ausgabe 3/2017
Elektronische ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-017-0215-z

Weitere Artikel der Ausgabe 3/2017

Alternative Fixation in Osteoporotic Fractures

  • Geriatric Orthopedics (E Meinberg, Section Editor)

Updates in the Evaluation of Older Women with Pelvic Floor Disorders

  • Geriatric Urology (H Richter, Section Editor)

Anesthesia Considerations for the Geriatric Patient

  • Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Prostate Cancer in the Elderly Male: Diagnostic and Management Considerations

  • Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Impact of Geriatric Syndromes on Diabetes Management

  • Nutrition, Obesity, and Diabetes (H Florez, Section Editor)

Thoracic Surgery in Older Patients

  • Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise